尊龙凯时
About us
尊龙凯时:Our Values
尊龙凯时:Development Milestone
Products
尊龙凯时:Product List for API
尊龙凯时:Recommended API
尊龙凯时:Product list for Chemicals and Intermediates
Product list for Chemicals and Intermediates
News
Contract Manufacturing
尊龙凯时:API and Pharmaceutical Intermediates
尊龙凯时:OTC and Generics
尊龙凯时:Investor Relation
尊龙凯时:PERIODIC REPORT
尊龙凯时:INTERIM REPORT
尊龙凯时:INVESTORS SERVICE
尊龙凯时:Contact Us
About us
News
尊龙凯时:Investor Relation
Products
尊龙凯时:Contract Manufacturing
尊龙凯时:Contact Us
Investor Relation
Investor Relation
尊龙凯时:PERIODIC REPORT
INTERIM REPORT
尊龙凯时:INVESTORS SERVICE
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
2024-06-03
Overseas Regulatory Announcement-Announcement on Citicoline Sodium Injection(4ml:0.5g) Having Passed the Generics Consistency Evaluation
2024-05-31
Overseas Regulatory Announcement-Announcement on Sodium Bicarbonate Injection Having Passed the Generics Consistency Evaluation
2024-05-29
Overseas Regulatory Announcement-Announcement on Escitalopram Oxalate Tablets(10mg) Having Obtained the Drug Registration Certificate
2024-05-22
Monthly Return of Equity Issuer on Movements in Securities for the month ended 3
2024-05-06
Proposed Amendments to the Articles of Association
2024-04-25
Announcement Notice of Board Meeting
2024-04-11
Overseas Regulatory Announcement-Announcement on Cefaclor Capsules of Wholly-own
2024-04-10
Overseas Regulatory Announcement-Announcement on Peramivir Injection Having Obtained the Notification of Approval of Supplementary Drug Application
2024-04-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
2024-04-02
<
...
4
5
6
7
8
9
10
...
>